POINT Biopharma Global Past Earnings Performance
Past criteria checks 4/6
POINT Biopharma Global has been growing earnings at an average annual rate of 58.2%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 135.4% per year. POINT Biopharma Global's return on equity is 22.8%, and it has net margins of 39.6%.
Key information
58.2%
Earnings growth rate
83.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 135.4% |
| Return on equity | 22.8% |
| Net Margin | 39.6% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates
Aug 20
We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth
Feb 01A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)
Oct 18Point Biopharma plummets on announcing common stock offering
Sep 13POINT Biopharma Global GAAP EPS of -$0.27 misses by $0.05
Aug 12Revenue & Expenses BreakdownBeta
How POINT Biopharma Global makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 244 | 97 | 23 | 113 |
| 30 Jun 23 | 241 | 97 | 21 | 107 |
| 31 Mar 23 | 236 | 98 | 20 | 96 |
| 31 Dec 22 | 227 | 98 | 19 | 82 |
| 30 Sep 22 | 0 | -79 | 16 | 64 |
| 30 Jun 22 | 0 | -72 | 16 | 56 |
| 31 Mar 22 | 0 | -56 | 14 | 42 |
| 31 Dec 21 | 0 | -46 | 12 | 34 |
| 30 Sep 21 | 0 | -37 | 9 | 28 |
| 30 Jun 21 | 0 | -23 | 5 | 18 |
| 31 Mar 21 | 0 | -18 | 4 | 13 |
| 31 Dec 20 | 0 | -13 | 4 | 9 |
Quality Earnings: PNT has high quality earnings.
Growing Profit Margin: PNT became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PNT's earnings have grown significantly by 58.2% per year over the past 5 years.
Accelerating Growth: PNT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PNT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: PNT's Return on Equity (22.8%) is considered high.